Publications & Posters

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

Download PDF

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

https://ascopubs.org/doi/abs/10.1200/PO.23.00235

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

Download PDF

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

https://doi.org/10.1016/j.leukres.2022.106884

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

https://doi.org/10.3389/fonc.2021.760789

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

Download PDF

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

https://doi.org/10.3324/haematol.2020.247346

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Download PDF

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

https://doi.org/10.1182/bloodadvances.2020002231

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

https://doi.org/10.1038/s41416-019-0724-y